BioNTech Future Growth
Future criteria checks 0/6
BioNTech's earnings are forecast to decline at 20.2% per annum while its annual revenue is expected to grow at 2% per year. EPS is expected to decline by 25.1% per annum. Return on equity is forecast to be -3.5% in 3 years.
Key information
-20.2%
Earnings growth rate
-25.1%
EPS growth rate
Biotechs earnings growth | 21.3% |
Revenue growth rate | 2.0% |
Future return on equity | -3.5% |
Analyst coverage | Good |
Last updated | 24 Apr 2024 |
Recent future growth updates
Recent updates
BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Apr 22We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
Mar 27BioNTech SE Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Mar 24BioNTech's Brew: Mixing COVID Legacy With Oncology Ambitions
Mar 20BioNTech Buys Into Autolus' Cell Therapy Tech - Why I Expect A Full Acquisition In Time
Feb 23BioNTech SE (NASDAQ:BNTX) Shares Could Be 30% Above Their Intrinsic Value Estimate
Feb 09Growth Investors: Industry Analysts Just Upgraded Their BioNTech SE (NASDAQ:BNTX) Revenue Forecasts By 20%
Jan 18Earnings Working Against BioNTech SE's (NASDAQ:BNTX) Share Price
Jan 02BioNTech (NASDAQ:BNTX) Could Easily Take On More Debt
Dec 11Time To Worry? Analysts Are Downgrading Their BioNTech SE (NASDAQ:BNTX) Outlook
Oct 22BioNTech (NASDAQ:BNTX) Has A Rock Solid Balance Sheet
Sep 11Is BioNTech (NASDAQ:BNTX) A Risky Investment?
Jun 13A Look At The Intrinsic Value Of BioNTech SE (NASDAQ:BNTX)
May 23BioNTech SE (NASDAQ:BNTX) Analysts Just Slashed This Year's Estimates
Mar 29These 4 Measures Indicate That BioNTech (NASDAQ:BNTX) Is Using Debt Safely
Mar 05A Look At The Fair Value Of BioNTech SE (NASDAQ:BNTX)
Feb 18Bearish: Analysts Just Cut Their BioNTech SE (NASDAQ:BNTX) Revenue and EPS estimates
Feb 02With EPS Growth And More, BioNTech (NASDAQ:BNTX) Makes An Interesting Case
Jan 26BioNTech SE (NASDAQ:BNTX) Held Back By Insufficient Growth Even After Shares Climb 36%
Nov 19BioNTech (NASDAQ:BNTX) Seems To Use Debt Rather Sparingly
Nov 09CDC advisory panel recommends COVID vaccines for children be included in federal program
Oct 19Do BioNTech's (NASDAQ:BNTX) Earnings Warrant Your Attention?
Oct 18Hong Kong approves BioNTech COVID vaccine for infants
Oct 12EMA starts rolling review of Pfizer/BioNTech's Omicron-subvariant adapted shot for kids
Oct 03BioNTech: A Tale Of 2 Companies
Sep 20European drug regulator panel backs approval of Pfizer/BioNTech's Omicron-adapted shot
Sep 12CDC advisors to vote on COVID Omicron vaccines on Sept. 1
Aug 30Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 2,778 | -636 | -492 | -185 | 15 |
12/31/2025 | 2,732 | -504 | -585 | -66 | 18 |
12/31/2024 | 2,796 | -552 | 324 | 594 | 19 |
12/31/2023 | 3,819 | 930 | 4,666 | 5,371 | N/A |
9/30/2023 | 6,618 | 2,751 | 4,690 | 5,350 | N/A |
6/30/2023 | 9,184 | 4,375 | 8,726 | 9,317 | N/A |
3/31/2023 | 12,213 | 6,238 | 8,493 | 8,850 | N/A |
12/31/2022 | 17,311 | 9,434 | 13,214 | 13,577 | N/A |
9/30/2022 | 18,565 | 10,322 | 12,277 | 12,549 | N/A |
6/30/2022 | 21,191 | 11,748 | 9,040 | 9,271 | N/A |
3/31/2022 | 23,303 | 12,863 | 5,066 | 5,251 | N/A |
12/31/2021 | 18,977 | 10,293 | 736 | 890 | N/A |
9/30/2021 | 13,790 | 7,493 | 1,198 | 1,338 | N/A |
6/30/2021 | 7,770 | 4,072 | -474 | -355 | N/A |
3/31/2021 | 2,503 | 1,197 | -376 | -270 | N/A |
12/31/2020 | 482 | 15 | -99 | -13 | N/A |
9/30/2020 | 165 | -410 | -382 | -326 | N/A |
6/30/2020 | 126 | -230 | -239 | -183 | N/A |
3/31/2020 | 110 | -192 | -268 | -222 | N/A |
12/31/2019 | 109 | -179 | -270 | -198 | N/A |
9/30/2019 | 144 | -122 | -220 | -138 | N/A |
6/30/2019 | 136 | -116 | -142 | -75 | N/A |
3/31/2019 | 132 | -77 | -136 | -55 | N/A |
12/31/2018 | 128 | -48 | -126 | -59 | N/A |
12/31/2017 | 62 | -86 | -110 | -53 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: BNTX's earnings are forecast to decline over the next 3 years (-20.2% per year).
Earnings vs Market: BNTX's earnings are forecast to decline over the next 3 years (-20.2% per year).
High Growth Earnings: BNTX's earnings are forecast to decline over the next 3 years.
Revenue vs Market: BNTX's revenue (2% per year) is forecast to grow slower than the US market (8.1% per year).
High Growth Revenue: BNTX's revenue (2% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: BNTX is forecast to be unprofitable in 3 years.